+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID04661020

Phase 2 Study of CD19 CAR-T Therapy Combined with Rituximab, Lenalidomide, and Zanubrutinib for Newly Diagnosed High-risk Large B-cell Lymphoma

Led by Zhejiang University · Updated on 2026-04-07

40

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating CD19 CAR-T therapy for patients with newly diagnosed high-risk large B-cell lymphoma LBCL. This phase II clinical trial, led by Zhejiang University, focuses on patients with CD19-positive LBCL, aiming to explore the treatments effectiveness and safety as a first-line therapy. The study includes newly diagnosed high-risk cases, defined by specific lymphoma subtypes and clinical scores. Participants receive a combination treatment involving rituximab, lenalidomide, and zanubrutinib ZR2, followed by a sequential infusion of CD19 CAR-T cells. The CAR-T cells are administered intravenously, with the study designed as a single-arm, single-center trial. This approach integrates immunotherapy and targeted cell therapy to assess their combined impact on this lymphoma. During the study, participants undergo various assessments, including evaluation of remission status three months after CAR-T therapy. Researchers will monitor overall response, survival rates, duration of response, and treatment-related side effects for up to two years following CAR-T infusion. Participants provide informed consent and are closely followed to measure treatment outcomes and safety over the study period.

CONDITIONS

Brief Title

CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

Research Team

H

He Huang, PhD

Y

Yongxian Hu, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here